Summary

Eligibility
for people ages 18-70 (full criteria)
Location
at San Diego, California and other locations
Dates
study started
estimated completion

Description

Summary

The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in improving symptoms of Neurogenic Lower Urinary Tract Dysfunction

Keywords

Neurogenic Bladder, Spinal Cord Injuries, Stroke, Multiple Sclerosis, Urinary Bladder, Neurogenic, SCONE

Eligibility

You can join if…

Open to people ages 18-70

  1. Subject is ≥ 18 and ≤ 70 years old at the time of enrollment/consent
  2. Subject has a diagnosis of NLUTD due to:
  3. Chronic, spinal cord injury at C3 to T8 classified as ASIA A-D on the AIS scale OR
  4. Multiple sclerosis; OR
  5. Stroke
  6. Subject has symptoms of urinary urgency (>50% high urge voids) or increased frequency of micturition/self-catheterization (more than once every 2 hours) or incontinence between voids or catheterizations (>5/day).
  7. Subject must demonstrate detrusor overactivity (unintentional detrusor contraction > 10 cm H2O) on clinical urodynamic studies.
  8. Subject has sterile urine or asymptomatic bacteriuria.
  9. Subject's score is > 28 on NBSS survey.
  10. Subject is at least one year post initial diagnosis at the time of enrollment (consent).
  11. Subject's medical condition is stable.
  12. Subject has adequate social support network to be able to participate in training and assessment sessions for the duration of the study, at the discretion of the Investigator.
  13. . Subject has been informed of the nature of the study, can understand the requirements of the study, agrees to participate, and has signed the IRB/EC-approved informed consent.

You CAN'T join if...

  1. Subject relies on an indwelling catheter (urethral or suprapubic) for bladder drainage.
  2. Subject relies on an indwelling catheter (urethral or suprapubic) for bladder drainage.
  3. Subject has participated in other transcutaneous or epidural spinal stimulation trials.
  4. Subject has congestive heart failure, pulmonary disease necessitating supplemental oxygen use, chronic kidney disease (Stage III or higher), chronic liver disease (Child Pugh class B or C) or poorly controlled diabetes (if diabetic, HbA1c > 8.0 within the preceding 6 months).
  5. Subject has a concurrent neurological disease affecting the central nervous system, other than spinal cord injury or multiple sclerosis or stroke.
  6. Subject has an implanted central or peripheral neuromodulator.
  7. Subject has symptomatic, clinically significant autonomic dysreflexia attacks (characterized by headache and systolic blood pressure greater than 180 mmHg) more than once a week.
  8. Subject is dependent on an electro-magnetic medical implant (e.g., cardiac pacemaker or implanted drug pump), ventilation support, or other external device.
  9. Subject has received intravesical botulinum toxin injection within 12 months preceding enrollment.
  10. . Subject's BMI is > 35.
  11. . Subject has history of morphologic bladder outlet obstruction (e.g., due to benign prostatic hyperplasia, urethral stricture and/or bladder neck contracture).
  12. . Subject has history of frequent symptomatic urinary tract infections, defined as receiving five or more courses of urinary tract infection-directed antibiotics within 12 months prior to enrollment.
  13. . For non-catheterizing subjects, post-void residual is > 100 mL measured by bladder ultrasound, bladder scanner, or one-time catheterization at the time of enrollment.
  14. . For female subjects, history or physical exam consistent with > Stage II pelvic organ prolapse as defined by the International Continence Society.
  15. . For male subjects older than 55 years of age,13,14 physical exam or medical imaging (e.g., transrectal ultrasound, abdominal/pelvic computed tomography or magnetic resonance imaging) consistent with prostate size > 50 cm.
  16. . Subjects with significant stress incontinence as defined by > 3 stress incontinence episodes per day, defined as incontinence episodes precipitated by increased intraabdominal pressure (e.g., cough, sneeze, Valsalva maneuvers, transfers, other forms of physical activity), stress incontinence demonstrated on physical exam or abdominal leak point pressure < 100 cm H2O at bladder volume less than 200ml per urodynamics study.
  17. . Subject is pregnant or trying to become pregnant; or is nursing.
  18. . Subject has limited life expectancy or co-morbid conditions, social/psychological problems, or cognitive impairments that, in the opinion of the Investigator, will preclude them from participation and completion of study procedures or requirements.
  19. . Subject has a medical condition or complications related to the use of certain medications that may affect validity of the study as determined by the Investigator.
  20. . Subject has a medical condition not listed above that may put the subject at risk as determined by the Investigator.
  21. . Subject is participating in or plans to participate in another research study that may interfere with study endpoints.
  22. . Subject is known or suspected to be non-compliant; and/or subject is unable or unwilling to comply with study requirements.

-

Locations

  • Univ of California, San Diego accepting new patients
    San Diego California 92093 United States
  • Rancho Research Institute accepting new patients
    Downey California 90242 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
SpineX Inc.
ID
NCT05301335
Study Type
Interventional
Participants
Expecting 130 study participants
Last Updated